Editorial: Preventing ovarian hyperstimulation syndrome.
Aboulghar
M A
MA
D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D005307:Fertilization in Vitro / Q000009:adverse effects; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000503:physiopathology / Q000517:prevention & control*; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism / Q000502:physiology*
D018491:Dopamine Agonists; D004873:Ergolines; D042461:Vascular Endothelial Growth Factor A; D000077465:Cabergoline